First Fridays Indy with Jay Miguel

3777 Priority Way South Drive,Indianapolis IN 46240

01 April, 2022

Description

Why First Fridays...Come learn something new and meet someone new. Jay McGill, Ph.D. is the Chief Operating Officer of the Indiana Biosciences Research Institute (IBRI) where he is responsible for the day to day scientific operations. In addition, Dr. McGill plays a key role in establishing both public and private collaborative relationships with the IBRI. Dr. McGill is a member of the Indiana Clinical and Translational Sciences Institute’s Executive Committee. Prior to joining the IBRI in January 2018, Dr. McGill spent 28 years at Eli Lilly and Company in a variety of positions. In his final role, Dr. McGill was the Senior Director, Lilly Research Laboratories Operations responsible for Science and Technology Partnerships where he served as the interface between academic institutions and scientists within Lilly Research Labs. In addition, Dr. McGill oversaw Lilly's portfolio of research based Public Private Partnerships and consortium participation. Dr. McGill brings a vast experience in collaboration, partnership, research operations and venture to this critical interface with Indiana’s innovation and academic research communities. In 2013 and 2014, Dr. McGill was on assignment as a loaned executive with BioCrossroads, where he held the title of Translational Scientific Officer. His responsibilities at BioCrossroads included the support of several initiatives at the Indiana Clinical and Translational Institute (Indiana CTSI) at the Indiana University School of Medicine. Dr. McGill was instrumental in establishing the Indiana CTSI–Covance partnership for a Phase One clinic within IU hospital and played a critical role in creating the Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC). Dr. McGill served as the Chief Operation Officer and Treasurer for the Fairbanks Institute for Healthy Communities. Leveraging his experience with 6-Sigma, Dr. McGill led the redesign of the process for industry sponsored clinical research engagement dramatically reducing the time line for contracting and start-up of industry sponsored clinical trials with IU School of Medicine. In addition to his work with the Indiana CTSI, Dr. McGill supported the creation of the Indiana Bioscience Research Institute (IBRI). Previous to his assignment at BioCrossroads, Dr. McGill was the Senior Director of Research Business Operations where his responsibilities included the oversight and management of all Research based (preclinical) collaborations, alliances, and outsourcing partners including chemistry, in vitro and in vivo biology, preclinical ADME and toxicology. Dr McGill was also responsible for the Research Quality and Compliance organizations. From December 2010 to June 2012, Jay served as the interim COO of the Lilly China Research Development Center (LCRDC) in Shanghai, China. After Eli Lilly announced its intentions to create an R&D site in China, Dr. McGill led a team to identify a location, construct the facility and establish the operations for LCRDC which opened in June 2012. After receiving a B.S. in chemistry from the University of Georgia and a PhD in organic chemistry from Indiana University, Dr. McGill joined Eli Lilly and Company in 1990 as a Senior Scientist in the Chemical Process Development Group. In 1998, Jay joined the Discovery Chemistry Research and Technologies organization where he held a number of positions including Head of the Custom Synthesis Lab, Director of the Discovery Chemistry Synthesis Group, Sr. Director - Global Chemistry Sourcing. In 2008, as part of reorganization within Lilly Research Laboratories all of the Research based sourcing groups (chemistry, in vitro and in vivo biology, tox and ADME) were consolidated under Dr. McGill’s leadership as Senior Director, External Research Operations. Dr. McGill has over 25 years of experience in pharmaceutical research and development, research collaborations, and outsourcing management. During his career he has been instrumental in creating and developing Eli Lilly’s collaborations in Asia, and establishing operations to support an external network of research based outsourcing partners and alliances. Dr. McGill is known for his leadership in the pioneering of novel and transformational partnership models.